Literature DB >> 2253244

Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.

S H Bigner1, P A Humphrey, A J Wong, B Vogelstein, J Mark, H S Friedman, D D Bigner.   

Abstract

Both permanent cultured cell lines and athymic mouse xenografts were established from two human glioblastomas. Biopsies from D-245 MG and D-270 MG contained amplified and rearranged epidermal growth factor receptor (EGFR) genes. Although the gene amplification and rearrangement seen originally was maintained in the xenografts, cultured cell lines established from these biopsies lost the amplified rearranged genes in vitro. Analysis of these cell lines and 11 additional permanent human glioma cell lines with normal EGFR gene copy number showed from 2.7 x 10(3) to 4.1 x 10(5) high affinity EGFRs/cell by radioreceptor assay. The RNase A protection assay showed minimal differences in the quantity of EGFR mRNA among the 13 glioma lines, while the D-245 MG and D-270 MG xenografts expressed approximately 10-20 times as much EGFR mRNA as the corresponding cell lines. Immunoprecipitation of EGFR from these lines, including D-245 MG and D-270 MG, demonstrated only the intact Mr 170,000 Da form, while truncated Mr 145,000 Da and 100,000 Da EGFR proteins were immunoprecipitated from the D-270 MG and D-245 MG xenografts, respectively. These studies demonstrate that gliomas with amplification of the EGFR gene are capable of establishing in culture but that the amplified rearranged genes are not maintained. Possible explanations are that the abnormal genes are lost during serial passage or that the cells with amplified rearranged genes only represent a minor subpopulation of cells, which are unable to grow in culture. In either case, these observations suggest that high expression and structural abnormalities of EGFR proteins generated by amplification and rearrangement of the EGFR gene provide a growth advantage for gliomas in vivo but not in vitro.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2253244

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  114 in total

Review 1.  Molecular parameters of head and neck cancer metastasis.

Authors:  Sanjay L Bhave; Theodoras N Teknos; Quintin Pan
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2011       Impact factor: 1.807

2.  EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.

Authors:  Costas G Hadjipanayis; Revaz Machaidze; Milota Kaluzova; Liya Wang; Albert J Schuette; Hongwei Chen; Xinying Wu; Hui Mao
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

3.  Proliferation and motility responses of primary and recurrent gliomas related to changes in epidermal growth factor receptor expression.

Authors:  M E Berens; M D Rief; J R Shapiro; D Haskett; A Giese; A Joy; S W Coons
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

4.  Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas.

Authors:  An-hua Wu; Jing Xiao; Lars Anker; Walter A Hall; Dale S Gregerson; Webster K Cavenee; Wei Chen; Walter C Low
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

5.  Evaluation of systemically administered radiolabeled epidermal growth factor as a brain tumor targeting agent.

Authors:  W Yang; R F Barth; R Leveille; D M Adams; M Ciesielski; R A Fenstermaker; J Capala
Journal:  J Neurooncol       Date:  2001-10       Impact factor: 4.130

6.  Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential.

Authors:  Marie-Thérése Stockhausen; Karina Kristoffersen; Louise Stobbe; Hans Skovgaard Poulsen
Journal:  Cancer Biol Ther       Date:  2013-11-01       Impact factor: 4.742

Review 7.  Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.

Authors:  Ana Markovic; Christine H Chung
Journal:  Expert Rev Anticancer Ther       Date:  2012-09       Impact factor: 4.512

Review 8.  Peptide vaccines for the treatment of glioblastoma.

Authors:  Adam M Swartz; Kristen A Batich; Peter E Fecci; John H Sampson
Journal:  J Neurooncol       Date:  2014-12-10       Impact factor: 4.130

9.  The GLI1 splice variant TGLI1 promotes glioblastoma angiogenesis and growth.

Authors:  Hu Zhu; Richard L Carpenter; Woody Han; Hui-Wen Lo
Journal:  Cancer Lett       Date:  2013-09-15       Impact factor: 8.679

10.  Products of cells from gliomas: IX. Evidence that two fundamentally different mechanisms change extracellular matrix expression by gliomas.

Authors:  P E McKeever; J Varani; S M Papadopoulos; M Wang; J P McCoy
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.